in Re: Akin Gump Strauss Hauer & Feld LLP

CourtCourt of Appeals of Texas
DecidedFebruary 21, 2008
Docket14-07-00402-CV
StatusPublished

This text of in Re: Akin Gump Strauss Hauer & Feld LLP (in Re: Akin Gump Strauss Hauer & Feld LLP) is published on Counsel Stack Legal Research, covering Court of Appeals of Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
in Re: Akin Gump Strauss Hauer & Feld LLP, (Tex. Ct. App. 2008).

Opinion

Petition for Writ of Mandamus Denied and Opinion filed February 21, 2008

Petition for Writ of Mandamus Denied and Opinion filed February 21, 2008.

In The

Fourteenth Court of Appeals

____________

NO. 14-07-00402-CV

IN RE AKIN GUMP STRAUSS HAUER & FELD, LLP; THE ROBINSON LAW FIRM; WILLIAMS, BIRNBERG & ANDERSEN, L.L.P.; MICHAEL MADIGAN; MICHAEL J. MUELLER; KENNETH M. ROBINSON; AND GERALD M. BIRNBERG, Relators

ORIGINAL PROCEEDING

WRIT OF MANDAMUS

O P I N I O N


This original proceeding arises out of a long-running fee dispute between a biotechnology company and the lawyers who represented the company in intellectual-property litigation.  The trial court below confirmed an arbitration award in favor of the lawyers and rendered a final judgment thereon.  More than seven years later, the lawyers asked the trial court for a remand to the original arbitration panel to resolve disputes regarding the meaning of the panel=s arbitration award.  The trial court denied the motion and also denied a motion to reconsider and to compel arbitration of these disputes before the original panel.  Presuming, without deciding, that such disputes can ever be remanded to the original arbitration panel after a trial court has confirmed the award and rendered final judgment thereon, we conclude that the trial court did not clearly abuse its discretion by denying the lawyers= motions.  Accordingly, we deny the lawyers= petition for a writ of mandamus.

                        I.  Factual and Procedural Background

Beginning in 1994, relators Akin Gump Strauss Hauer & Feld LLP, The Robinson Law Firm, Williams Birnberg & Andersen, L.L.P., Michael Madigan, Michael J. Mueller, Kenneth M. Robinson, and Gerald M. Birnberg (collectively hereinafter the ALawyers@) represented real party in interest Tanox Biosystems, Inc. as plaintiff in certain litigation based on Tanox=s claims against Genentech, Inc. and other companies based on Genentech, Inc.=s alleged violation of a confidentiality agreement and misappropriation of Tanox=s trade secrets (hereinafter, ATrade Secret Claims@).[1]  The Lawyers and Tanox executed a contingency fee agreement (the AFee Agreement@) under which the Lawyers would be compensated only out of any recovery Tanox obtained as a result of the litigation.[2]  Tanox agreed to pay the Lawyers a contingent fee calculated on a sliding scale:  25% of the first $32 million recovered on behalf of Tanox, 33 1/3% of the recovery from $32 million to $60 million, 40% of the recovery from $60 million to $200 million, and 25% of the recovery over $200 million.   Tanox agreed that, in the event the case was settled (whether before, during, or after trial), the first $8 million of recovery would be paid to the Lawyers, Aregardless of whether the total recovery amounts to or is less than $32 million.@


Under the Fee Agreement, the amount recovered on behalf of Tanox that was subject to the above percentages, included, but was not limited to the following:

(i) all cash, monies, or substantial equivalent recovered by Tanox as a result of the litigation, plus (ii) the economic value to Tanox of all tangible property (real, personal, or mixed) obtained for Tanox as a result of the litigation . . . plus (iii) all future payments (such as, by way of example, licensing fees, royalties, and similar future payments) Tanox becomes entitled to receive as a result of the litigation; provided, however, that with respect to royalties or similar future payments received from defendants, Tanox will pay the [Lawyers] 10% of any such amounts, to be paid . . . until such time as the Acontingent fee@ has been paid in full or the Alimitations on contingent fee@ [no more Acontingent fee@ as to royalties after aggregate Acontingent fee@ for all categories reaches $300 million and total contingent fee cannot exceed $500 million in the aggregate] have been reached.

The Fee Agreement also reflected the parties= recognition that the Trade Secret Claims might be resolved by a Anew business arrangement@ between Tanox and one or more of the companies against which Tanox had asserted the Trade Secret Claims.  Tanox agreed that, in the event of settlement in the form of a new business arrangement, the Lawyers also would receive the percentage contingent fees based on A[a]ny cash, money, or substantial equivalent, any tangible property, and any future payments (such as licensing fees, royalties, income from third parties with respect to defendants= intellectual property, and similar future payments) received by Tanox as a result of the litigation, on account of such new business arrangement. . . .@


In 1996, Tanox and Genentech, Inc. (hereinafter AGenentech@) agreed to settle the litigation.  Terms of the settlement included a $16 million cash payment from Genentech to Tanox and a new business arrangement between Tanox, Genentech, and Ciba-Geigy, Ltd. for development of the allergy drug.  The parties outlined the new business arrangement in a document entitled AOutline of Terms for Settlement of the Litigations among Genentech, Inc., Genentech International Limited, Tanox Biosystems, Inc. and Ciba-Geigy, Limited, relating to Anti-IgE Inhibiting Monoclonal Antibodies@ (hereinafter the AOutline of Terms@).  The parties listed in the title of this document signed the document and attached it as an exhibit to the Settlement and Cross-Licensing Agreement.  Under the settlement, Genentech and Ciba-Geigy agreed to pay to Tanox royalties and certain payments tied to the achievement of milestones in the forecasted development of the product. 

Although the parties provided in the Fee Agreement that Tanox would not

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Brown v. Witco Corporation
340 F.3d 209 (Fifth Circuit, 2003)
Allied-Bruce Terminix Cos., Inc. v. Dobson
513 U.S. 265 (Supreme Court, 1995)
U.S. Energy Corp. v. Nukem, Inc.
400 F.3d 822 (Tenth Circuit, 2005)
In Re Prudential Insurance Co. of America
148 S.W.3d 124 (Texas Supreme Court, 2004)
In Re Cerberus Capital Management, L.P.
164 S.W.3d 379 (Texas Supreme Court, 2005)
In Re D. Wilson Const. Co.
196 S.W.3d 774 (Texas Supreme Court, 2006)
Katz v. Bianchi
848 S.W.2d 372 (Court of Appeals of Texas, 1993)
Hamm v. Millennium Income Fund, L.L.C.
178 S.W.3d 256 (Court of Appeals of Texas, 2005)
Golden Eagle Archery, Inc. v. Jackson
24 S.W.3d 362 (Texas Supreme Court, 2000)
In Re Nestle USA-Beverage Division, Inc.
82 S.W.3d 767 (Court of Appeals of Texas, 2002)
Harris County Appraisal District v. West
708 S.W.2d 893 (Court of Appeals of Texas, 1986)
Tanox, Inc. v. Akin, Gump, Strauss, Hauer & Feld, L.L.P.
105 S.W.3d 244 (Court of Appeals of Texas, 2003)
National Liability & Fire Insurance Co. v. Allen
15 S.W.3d 525 (Texas Supreme Court, 2000)
L & L Kempwood Associates, L.P. v. Omega Builders, Inc.
9 S.W.3d 125 (Texas Supreme Court, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
in Re: Akin Gump Strauss Hauer & Feld LLP, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-akin-gump-strauss-hauer-feld-llp-texapp-2008.